Search Results for “research” – Page 29 – media

MNCs in China, looking for a new era of survival philosophy

Multinational pharmaceutical companies are under increasing pressure. Especially when the US market, the world’s largest pharmaceutical market, has undergone tremendous changes due to the Inflation Reduction Act, the importance of the Chinese market has once again been highlighted. However, all signs indicate that it is becoming increasingly difficult to get a bigger piece of the pie in the Chinese market. In recent years, the reform policies introduced by the state at the pharmaceutical level have exceeded the changes in the previous decades. The continued advancement of medical reform policies such as medical insurance negotiations and national centralized procurement, coupled with the epidemic, anti-corruption, capital winter, local generic drugs, and the rise of innovative forces, have intensified the challenges of the entire industry. Therefore, we see that the past two years have become a strategic turbulence period for MNCs in China. While tapping the potential of the domestic market, they are ...
- Source: drugdu
- 68
- November 7, 2024
Kejun Pharmaceuticals Completes B+ Round of Phased Financing

On October 31, Shanghai Kejun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Kejun Pharmaceutical”) announced the completion of its B+ round of phased financing. This round of financing was led by Guoxin Innovation Equity, and other major investors included Aeon Group and Infinity Capital, and the original investor Honghai Capital also continued to make additional investments. Qidian Capital served as the financial advisor for this round of financing and will continue to provide financing services to Kejun Pharmaceutical in the future. Kejun Pharmaceutical stated that the funds raised from this financing will be used to accelerate the clinical development of CG-0255, a core product in the cardiovascular field. About Kejun Pharmaceutical Kejun Pharmaceutical was established in Zhangjiang, Shanghai in 2018, focusing on the treatment of cardiovascular and cerebrovascular diseases and antiviral diseases, and focusing on the research and development of small molecules and nucleic acid drugs. At present, Kejun ...
- Source: drugdu
- 53
- November 7, 2024
Design multi state and functional proteins using sequence space diffusion model

Protein Denoising Diffusion Probabilistic Models (DDPM) can efficiently generate novel proteins that meet specific properties and functional requirements, and have significant value in the field of protein design. Although many current models, such as RFdiffusion and Chroma, have shown excellent performance in generating protein three-dimensional structures, there are still challenges in generating proteins with sequence specificity and functional properties, and these models often require a lot of time and computational resources for training. David Baker’s team at the University of Washington has proposed a new solution to address this challenge. They believe that diffusion in sequence space can more effectively learn more knowledge from the current large amount of protein sequence data. Therefore, the research team developed a sequence space diffusion model ProteinGenerator based on RoseTTAFold, which can generate protein sequences and structures that meet the required properties. Subsequently, the research team further successfully designed multiple proteins with different functions ...
- Source: drugdu
- 53
- November 6, 2024
5 innovative drugs included in breakthrough treatment varieties

Breakthrough treatment varieties refer to innovative drugs or improved new drugs used to prevent and treat diseases that seriously endanger life or seriously affect quality of life, and for which there are no effective prevention and treatment methods or sufficient evidence to show significant clinical advantages compared to existing treatment methods. After obtaining this recognition, it can accelerate the review process, accelerate the drug development process, and solve the unmet clinical needs of patients. In the past October, the CDE official website plans to include 5 breakthrough therapy varieties, including 1 therapeutic vaccine, 3 ADC drugs, and 1 monoclonal antibody drug. The following are introductions to 5 innovative drugs for reference only. 1. TVAX-008: Hepatitis B On October 14th, Nanjing Yuanda Weixin Biopharmaceutical Co., Ltd. TVAX-008 applied to be included in the breakthrough treatment category, suitable for the treatment of chronic hepatitis B virus (HBV) infection. TVAX-008 is a therapeutic ...
- Source: drugdu
- 70
- November 6, 2024
Two innovative medical devices have been approved for market launch

Recently, the National Medical Products Administration announced the approval of the registration applications for two innovative products, Yabonixi Medical Technology (Suzhou) Co., Ltd.’s “knee joint prosthesis system” and Shanghai Xinwei Medical Technology Co., Ltd.’s “intracranial aneurysm embolization assisted stent”. Yabonixi Medical offers freedom of movement in all aspects Yabonixi Medical is a wholly-owned subsidiary of Jiaoying Medical Equipment (Shanghai) Co., Ltd., dedicated to the research, development, production, and sales of high-end orthopedic medical equipment, minimally invasive surgical medical equipment, and more. Yabonixi Medical was founded by Dr. Yao Jianqing, a leading figure in the international orthopedic field. It is reported that Yao Jianqing is an experienced veteran in the field of medical devices, with 36 years of rich experience in medical device and tissue engineering research and industrialization. He has served as the Global R&D Senior Director and Asia Pacific R&D Senior Director of ZimmerBiomet, a joint company. Yao Jianqing ...
- Source: drugdu
- 57
- November 6, 2024
Another GLP-1 drug king, is it on the way?

Recently, the Q3 financial reports of MNCs have been released one after another, and some are happy and some are sad. When a number of MNCs began to lower their full-year EPS, Amgen’s Q3 financial report earnings gave a high score answer sheet. Among them, Amgen’s total revenue in the third quarter increased by 23%, and its GAAP net earnings per share (EPS) increased by 62% year-on-year, from US$3.22 to US$5.22. What is more imaginative is that with the data catalysis of the new macromolecular weight loss drug AMG133, this macromolecular antibody that goes against the grain and antagonizes GIPR may become Amgen’s next gold mine. According to Amgen’s Q3 2024 financial report, the most significant year-on-year growth is LUMAKRAS (AMG510) – a targeted drug for KRASG12C mutation-positive lung cancer. The sales ceiling of this gene mutation in European and American countries will be much higher than that in Asian ...
- Source: drugdu
- 60
- November 6, 2024
China’s time-honored brands, mergers and acquisitions accelerate

Recently, Beijing Tong Ren Tang issued an announcement on foreign investment, stating that its holding subsidiary Beijing Tong Ren Tang Commercial intends to sign a “Share Transfer Agreement” with Honghui Technology, Daopei Hongde, Honghui Pharmaceutical, Wang Desheng and Wang Aixiao, and intends to pay about 105 million yuan to acquire Honghui Technology’s 51% stake in Honghui Pharmaceutical. As a pharmaceutical and medical device operating company, Honghui Pharmaceutical was established in 1994 and is mainly engaged in pharmaceutical research and development, pharmaceutical production and sales, and medical device operations. The performance in the first half of 2024 showed that Honghui Pharmaceutical achieved revenue of 844 million yuan and net profit of 25.5713 million yuan (unaudited). In 2023, Honghui Pharmaceutical achieved a net profit of 228 million yuan (unaudited). At present, Honghui Pharmaceutical is still a long way from catching up with last year’s full-year net profit. Tong Ren Tang is a ...
- Source: drugdu
- 61
- November 6, 2024
The World’s First Targeted Innovative Drug for Hepatitis B Approved for Market

On October 30, Xi’an Xintong Pharmaceutical Research Co., Ltd. held a press conference in the Silk Road Innovation and Smart Valley of Xi’an High-tech Zone to announce the approval of “Xinshi Mu,” a first-class innovative drug targeting hepatitis B. It is the commercial name approved for the drug Preadfovir mesylate tablets, which is indicated for the treatment of chronic hepatitis B in adults. The drug utilizes the HepDirect liver-targeted delivery system to concentrate the active ingredients in the target organ, enhancing efficacy and reducing toxicity. This makes it the world’s first approved liver-targeted innovative drug for hepatitis B. Zhang Denge, chairman of Xintong Pharmaceutical, stated that “Xinshi Mu” is part of the national major new drug creation projects during the 12th and 13th Five-Year Plans, with research beginning in 2011, and it took 13 years to gain approval for market release. Wang Liping, the Drug Safety Director of the Shaanxi ...
- Source: drugdu
- 49
- November 6, 2024
$1.4 billion deal highlights the future of Alzheimer’s disease therapy

The development of therapies for Alzheimer’s disease has always caused many developers to feel exhausted, and now AbbVie has also increased its investment in neurodegenerative diseases. AbbVie has agreed to spend $1.4 billion to acquire Aliada Therapeutics, whose main acquisition asset is Aliada’s authorized Alzheimer’s disease candidate drug ALIA-1758 from Johnson&Johnson. Its mechanism of action is still an anti beta amyloid protein (3pE-A β) antibody, but the unique feature of ALIA-1758 is that it can cross the blood-brain barrier, greatly improving the brain’s absorption rate. Aliada started a phase 1 trial among healthy volunteers in May, but AbbVie believes the timing is ripe for acquisition. Previously, AbbVie made the decision to abandon its internal Alzheimer’s disease asset ABBV-916. This anti beta amyloid antibody has no significant difference in safety and efficacy compared to the already marketed monoclonal antibody therapy for Alzheimer’s disease. Therefore, AbbVie decided to terminate the development ...
- Source: drugdu
- 57
- November 5, 2024
Interphex

Organiser：Pharmaceutical Research and Manufacturers of America (PhRMA) Time： April 1st – 3rd, 2025 Address：655 West 34th Street, New York, NY 10001-1188, USA Exhibition hall：Javits Convention Center, NYC Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, hormones, cephalosporins, macrolides, central nervous system drugs, and other western medicine raw materials Excipients & Dosage Forms: Excipients, fluids, enteric coatings, antioxidants, sweeteners, osmotic agents, preservatives, disintegrants, clarifiers, pH adjusters, etc. Natural Extracts: Plant extracts, animal extracts, dietary fibers, cosmetic ingredients About Interphex： Interphex, the Biopharmaceutical Manufacturing & Technology Exhibition in New York, USA, is a leading event in the pharmaceutical and biotechnology industries, merging industry innovations with expert-led conferences. Since its inception in 1979, it has been the most trusted life science exhibition across both chemical and biopharmaceutical sectors in North America. Exhibitors have the opportunity to meet with decision-makers from top pharmaceutical companies worldwide through this exhibition.
- Source: drugdu
- 64
- November 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.